anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients receive educational handouts about physical activity and are encouraged to increase physical activity to at least 420 minutes per week. Patients wear physical activity tracking device daily and upload data at least once a week to the device app/website. Patients also access the limited version of device app/website to get basic information related to their physical activity for 6 months.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely pediatric dentistry, and may be used for preventing dental caries in children. Method of obtaining a calcium-phosphate-fluorine-containing gel for tooth enamel remineralisation in children involves preparation of an aqueous solution of a calcium salt, an aqueous solution of phosphate salts and fluoride, mixing them with hot aqueous solutions of sodium salt of carboxymethyl cellulose (CMC) and after cooling with each other. Initial components used are dehydrated calcium chloride, potassium dihydrophosphate, sodium fluoride, on their basis aqueous solutions of calcium chloride, potassium dihydrophosphate and sodium fluoride are obtained from the calculation so that in the finished gel means the calcium content is 0.5 %, the phosphorus content is 2 %, the fluorine content is 0.02 % or 0.035 % or 0.05 %. Each of the solutions is mixed with hot 4 % aqueous solution of CMC, cooled, combined, adding a mixture of phosphate and fluoride to calcium, well mixed, correcting the pH of the finished gel using 40 % KOH solution to value of 6.5±0.1. Invention enables to obtain weakly acidic gels containing active ions of calcium, fluorine and phosphate, capable of participating in mineralization processes of tooth enamel. At that, value of fraction of active forms of fluoride ions close to prototype is achieved at lower initial concentrations of sodium fluoride introduced into gel.EFFECT: gel content of not more than 500 ppm enables prescribing it to children aged 3 to 15 years for home independent use.1 cl, 3 ex
This present invention describes a method of diagnosing and treating neuropathic pain, Bell's palsy, viral sore throat, pain due to burns, including sunburn, and pain and itching due to insect bites with compositions of essential aromatic oils, all of which contain  Pelargonium graveolens  (also called geranium oil bourbon or GOB). This invention discloses compositions of one or more of five other essential aromatic oils, particularly lavender, bergamot, blue chamomile, eucalyptus and tea tree, which when added to GOB acts synergistically with the GOB. These compositions can be used alone or in a composition with a pharmaceutically acceptable carrier in topical or oral dosage form. The present invention is an improvement in the methods and expansion of uses as stated in the previous United States Patent issued in 1993 entitled “Diagnosis and Treatment of Various Neuralgias” (Frome)—U.S. Pat. No. 5,260,313.
Improving rates of blood pressure (BP) control among adults with hypertension is a key step in reducing rates of myocardial infarction, stroke, and heart failure, and lowering overall mortality from cardiovascular disease. Unfortunately, over half of patients prescribed medication for hypertension do not take their medication as prescribed, leading to a high percentage of patients (45%) who are unable to reach their target BP despite being treated with antihypertensive medication. Low medication adherence has been linked with higher rates of myocardial infarction, stroke, and angina, as well as reduced life expectancy. Previously tested interventions to improve adherence to antihypertensive regimens have had limited efficacy, largely due to an underlying assumption that a single, standardized intervention approach will address all patients' reasons for nonadherence. Tailoring adherence interventions using a Managed Problem Solving approach will permit addressing each patient's reasons for nonadherence. This project will test the feasibility of the Medication Adherence Problem Solving for Hypertension (MASH) telehealth intervention, tailored to each participant's reasons for low adherence to their antihypertensive medication. The intervention is designed to assess beliefs about hypertension, beliefs about medications, and barriers to effective medication-taking We will then deliver intervention strategies to address each patient's problematic beliefs and barriers, applying the 5 steps of Managed Problem Solving. The proposed project aims are to 1) Assess the feasibility of MASH to improve antihypertensive medication adherence among adults with hypertension (HTN) by tracking recruitment, participant engagement and satisfaction with the intervention, as well as retention in the study; 2) Obtain estimates of efficacy of MASH compared to usual care on improving antihypertensive adherence as measured by electronic monitoring caps (MEMS) and lowering BP among persons with elevated BP at baseline over 12 weeks to inform future power analyses for a full-scale trial; and 3) Obtain estimates of other model parameters necessary to inform future power analyses for a full-scale intervention trial, including (a) intervention effects on targeted reasons for nonadherence (beliefs, barriers, perceived side-effects) and their subsequent association with medication adherence; (b) strength of covariate effects (e.g. education, household size, employment); and (c) the within-participant correlation between assessments. If successful, this intervention can also serve as a model for improving medication adherence in other chronic conditions and improve health outcomes for the half of patients with chronic conditions who struggle to manage their medications.
A new virus, Hepatitis C virus (HCV), which has proven to be the major etiologic agent of blood-borne NANBH, was discovered by Applicant. The initial work on this virus, which includes a partial genomic sequence of the prototype HCV isolate, is described in EPO Pub. No. 318,216, and PCT Pub. No. WO 89/04669. The present invention, which in part is based on new HCV sequences and polypeptides which are not disclosed in the above-cited publications, includes the application of these new sequences and polypeptides in immunoassays, probe diagnostics, anti-HCV antibody production, PCR technology, and recombinant DNA technology. Included within the invention also are novel, immunogenic polypeptides encoded within clones containing HCV cDNA, novel methods for purifying an immunogenic HCV polypeptide, and antisense polynucleotides derived from HCV cDNA.
Mechanism of Action

Coartem Tablets, a fixed ratio of 1:6 parts of artemether and lumefantrine, respectively, is an antimalarial agent. Artemether is rapidly metabolized into an active metabolite DHA. The antimalarial activity of artemether and DHA has been attributed to endoperoxide moiety. The exact mechanism by which lumefantrine exerts its antimalarial effect is not well defined. Available data suggest lumefantrine inhibits the formation of β-hematin by forming a complex with hemin. Both artemether and lumefantrine were shown to inhibit nucleic acid and protein synthesis. 

Activity In Vitro and In Vivo

Artemether and lumefantrine are active against the erythrocytic stages of P. falciparum. 

Drug Resistance

There is a potential for development of resistance to artemether and lumefantrine. Strains of P. falciparum with a moderate decrease in susceptibility to artemether or lumefantrine alone can be selected in vitro or in vivo, but not maintained in the case of artemether. Alterations in some genetic regions of P. falciparum [multidrug resistant 1 (pfmdr1), chloroquine resistance transporter (pfcrt), and kelch 13 (K13)] based on in vitro testing and/or identification of isolates in endemic areas where artemether/lumefantrine treatment was administered, have been reported. The clinical relevance of these findings are not known.
PURPOSE:To obtain a percutaneous absorption promoter having excellent percutaneous absorption promoting effects, improved safety and feeling in use, containing an anionic surface active agent and a surface active agent containing a nitrogen atom in the molecule except the anionic surface active agent as active ingredients. CONSTITUTION:The titled promoter containing one or more anionic surface active agents (e.g. fatty acid soap, ether carboxylic acid,salt, alkylsulfonate, etc.) and one or more of surface active agents containing a nitrogen atom in the molecule (e.g. carboxybetaine, sulfobetaine, amine oxide, fatty acid alkanolamine, etc.) except the anionic active agent as active ingredients. Predonisolone, indomethacin, chlorpheniramine, etc., may be cited as a medicinal component to increase medicinal effects by the use of the percutaneous absorption promoter. When the medicinal component is blended with the percutaneous absorption promoter and applied to the skin, the component is rapidly absorbed.
This is a long term randomized controlled study looking at the effect of a Behavioral program on BMI in a population 10-20years old with a BMI greater than or equal to 85%. The intervention is a Behavioral education program which meets monthly for 4 hour session and includes exercise, education, empowerment and incentives. Both groups are referred to a dietician. The primary outcome is change in BMI and the secondary outcome is improvement in fasting metabolic parameters (lipid panel, insulin, glucose).
A gel facial mask comprises facial mask base cloth composed of cellulose acetate fiber, chitosan fiber and other fibers, wherein the cellulose acetate fiber content is 0-98wt.%, the chitosan fiber content is 2-50wt.%, and the other fibers content is 0-90wt.%. The other fibers comprise one or two or more of cotton fibers, viscose fibers, cuprammonium fibers and tencel fibers. The gel mask accelerates the gelling process after contacting the skin. The gel-forming time of the gel mask after contacting the skin is controllable and ranges from 20 s to 60s. After the gel mask is added with water, the temperature of the mask is reduced, so that the contacted skin is cooled. The invention also discloses a preparation method of the gel mask, which is obtained by positive pressure jet flow treatment and negative pressure air drying treatment. The gel mask disclosed by the invention is soft in hand feeling, can be used for obtaining a soft and transparent skin care mask with water retention and moisture retention by only soaking in a small amount of water, and is good in skin fitting property, convenient to carry and easy to unfold for use.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to preparing the new bioflavanoid preparation diquertin. Diquertin has total bioflavanoids at the following ratio of components, %: dihydroquercitin, 90-92; dihydrokaempferol and naringenin, 8-10, at condition that naringenin level does not exceed 2%. Diquertin is obtained by larch wood saw-dust extraction with an aqueous-acetone extract in acid medium immediately after raw treatment with boiling water. The end product is crystallized from alcohol or an aqueous-spirituous solution. Diquertin regulates metabolic processes and can be used in complex therapy treatment. EFFECT: improved method for preparing, enhanced effectiveness. 2 cl, 4 tbl, 2 dwg
PURPOSE:To obtain the titled composition containing a monomeric mixture consisting of a polyfunctional urethane based monomer and methacrylic resin syrup and visible ray polymerization initiator consisting of an aromatic mercaptocarboxylic acid, alpha-diketone and amine having a polymerizable unsaturated group. CONSTITUTION:The tiled composition obtained by blending 100pts.wt. monomeric mixture consisting of a compound expressed by formula I, II or III (R1 is H or CH3; R2 is 1-8C alkylene or a group expressed by formula IV) with 0.01-40 pts.wt. visible ray polymerization initiator consisting of an aromatic mercaptocarboxylic acid, e.g. o-mercaptobenzoic acid, alpha-diketone, e.g. camphorquinone, and amine having a polymerizable unsaturated group, e.g. dimethylaminoethyl methacrylate. The composition is capable of improving the aesthetic feeling of plastic dentures, remarkably improving surface hardness as well as abrasion resistance thereof at the same time and suppressing propagation of various germs by water absorption.
Scientific evidence has linked diabetes to a higher incidence and increased aggressiveness of breast cancer; however, mechanistic studies of the numerous regulators involved in this process are insufficiently thorough. Advanced glycation end products (AGEs) play an important role in the chronic complications of diabetes, but the mechanisms of AGEs in breast cancer are largely unexplored. In this study, we first demonstrate that high AGE levels in breast cancer tissues are associated with the diabetic state and poor patient outcomes. Furthermore, AGEs interact with the receptor for AGEs (RAGE) to promote breast cancer cell migration and invasion. Mechanistically, based on RNA sequencing (RNA-seq) analysis, we reveal that growth arrest and DNA damage gene 45α (GADD45α) is a vital protein upregulated by AGEs through a P53-dependent pathway. Next, GADD45α recruits thymine DNA glycosylase for base excision repair to form the demethylation complex at the promoter region of MMP-9 and enhance MMP-9 transactivation through DNA demethylation. Overall, our results indicate a critical regulatory role of AGEs in patients with breast cancer and diabetes and reveal a novel mechanism of epigenetic modification in promoting breast cancer metastasis.
All participants will practice a motor task (the Scooping Task) for 2 consecutive days. Each day of training, participants will complete 50 trials (10 blocks of 5 trials each) with their more affected arm and 20 trials (10 blocks of 2 trials each) with their less affected arm. One trial of the task will involve using a spoon to scoop beans, one at a time, from one cup to another while seated at a table. Participants will be asked to complete as many scoops as possible from the cup closest to them to the cup farthest from them within 30 seconds in an anterior-posterior direction. One successful repetition occurs when at least one bean is transferred. The number of successful repetitions within a 30 second trial is then counted. Training for the experimental group will include the practice variable of interest.
The invention belongs to the technical field of biological medicines, and relates to an immunosuppressive polypeptide, a preparation method thereof and application thereof in preparing medicines for treating rheumatoid arthritis. The amino acid sequence of the immunosuppression polypeptide provided by the invention is shown in any one of SEQ ID NO. 2, SEQ ID NO. 5, SEQ ID NO. 7 or SEQ ID NO. 12-15. The immunosuppression polypeptide is an allosteric peptide designed by taking citrullinated antigen peptide as prototype peptide, can inhibit activation of citrulline antigen in autoantigen to an immune system, thereby achieving the purpose of treating rheumatoid arthritis, and can be used for preparing medicines for treating rheumatoid arthritis. The invention starts from the autoantigen for inducing the rheumatoid arthritis, achieves the aim of treating the rheumatoid arthritis by specifically inhibiting the activation of the autoantigen to an immune system, and has potential treatment effect and safety superior to those of wide immunosuppressive drugs.
the investigators choose 60-80-year-old Garden I or II patients with initial fractures. Hollow nails are the first choice for treatment of these patients. However, the spatial arrangement of hollow nails, local blood supply, and biomechanical properties have a greater impact on the prognosis of fractures. , There are still some controversies, which are also the current research hotspots. Our research conclusions may increase the success rate of hip preservation and will guide the treatment of these patients. This study is based on the precise placement of nails by the Dimensity orthopedic robot, and compares the vascular injury of the femoral head before and after the nail placement (femoral head enhanced MRI) to assess the prognosis of the patient. The influence of blood supply and prognosis of femoral neck fracture in the elderly.
The Phase 1b portion is an open label, dose de escalation, single arm study designed to assess the safety and tolerability of up to 3 dose levels of U3- 1287 in combination with trastuzumab plus paclitaxel and will determine the recommended Phase 2 dose (RP2D) of U3 1287. The first cohort will receive U3- 1287 18 mg/kg intravenously (IV) in combination with trastuzumab plus paclitaxel once every 3 weeks (q3w).
Patients receive either mFOLFOX7 plus BEV, or Capecitabine + OXAL (XELOX) plus BEV. mFOLFOX7 + BEV is comprised of OXAL IV over 2 hours, LV calcium IV over 2 hours, and 5FU IV over 46-48 hours on day 1. Patients also receive BEV IV over 10-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. XELOX + BEV is comprised of OXAL IV over 2 hours on day 1 and capecitabine PO BID on days 1-14. Patients also receive BEV IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Gabapentin at a dose of 300mg three times a day for 2 days before and 5 days after each taxane infusion. Administered orally.
An acidic solution is applied to the tooth surface in the oral cavity and has the ingredients thymol, eucalyptol and menthol. It kills bacteria in the mouth and makes the environment acidic. The acidity in the oral cavity causes demineralization to occur, releasing calcium and phosphate through open pores in the tooth surface. The acidic solution is removed from the oral cavity after a predetermined amount of time. The non-acidic mouthwash is applied to the tooth surface subsequent to the removal of the acidic solution. It has sodium fluoride and works to neutralize acidic conditions in the oral cavity allowing remineralization to occur. Calcium and phosphate ions fill the open pores in the tooth surface, hardening the enamel. After a predetermined amount of time the user removes the non-acidic solution.
BACKGROUND: The Pediatric Early Warning Score (PEWS) is a clinical tool used to identify children at risk for clinical deterioration, but its utility remains debated, particularly in high-resource settings. Our objective with this study was to assess the predictive performance of the PEWS for unplanned PICU transfers after pediatric rapid response team (RRT) activation.
METHODS: A retrospective cohort study at a tertiary care academic children's hospital included all hospitalized patients up to 21 years old who had RRT activations between August 2021 and July 2022. Demographic and clinical data, the primary reason for RRT activation, and the modified Brighton PEWS were collected. The primary outcome was PICU transfer following RRT activation, and the secondary outcome was rapid escalation of care within 4 hours after RRT activation. Sensitivity, specificity, and area under the receiver operating characteristic curve (AUROC) were calculated at multiple PEWS thresholds.
RESULTS: Of 297 RRT activations in 244 patients, 183 (63%) resulted in a PICU transfer, 75% of which were due to respiratory concerns. The PEWS was recorded in 89% of RRT activations within the preceding 4 hours. There was no significant difference in the PEWS between patients with or without PICU transfer or rapid escalation of care. The sensitivity, specificity, and AUROC of PEWS for predicting PICU transfer or rapid escalation of care were low (AUROC 0.495-0.613).
CONCLUSIONS: PEWS within 4 hours before RRT activation was a poor predictor of PICU transfer or rapid escalation care. Further work is needed to develop a more sensitive and specific tool.
The patients will be divided in two groups using a computer generated randomization software. The first will be the MACPERAN group (controlled) and the other will be the NEWBUTIN group (variable). The controlled group will be treated with post-operative regimen in accordance with the standard protocol of the Chungmu Hospital, MACPERAN(Metoclopramide hydrochloride monohydrate 8.46 mg/2ml/A) thru IV twice in a day while the variable group will be given a single dose of NEWBUTIN SR 300 mg Tab orally one hour prior to the said operation time and another 300 mg orally as soon as the patient wakes post operatively.

A clinical research coordinator will monitor the patient until 48 hours post-operative. First time frame will be from 0-2 hours once patient is transferred to the ward followed by 2 hours to 24 hours and 24-48 hours post ward transfer. All patients will be assessed using the simplified risk score of Apfel et al. to determine who have the risk factors for PONV. The episodes of nausea and vomiting will be recorded taking note of its intensity and frequency on the said three time frames. Nausea is defined as a subjectively unpleasant sensation associated with an awareness of the urge to vomit; vomiting is defined as the forceful expulsion of gastric contents through the mouth. As retching is similar to vomiting in all aspects, except for the expulsion of gastric contents, it was considered as vomiting. The efficacy of anti-emetic medication (NEWBUTIN 300 mg/tab) will be assessed by monitoring the frequency and severity of nausea, vomiting, and PONV (which was regarded as the primary outcome). The severity of nausea will be graded on a four-point scale, where 0= no nausea, 1= mild nausea, 2= moderate nausea, and 3= severe nausea.Then the frequency will be assessed by monitoring how often the patient experienced these episodes (nausea and vomiting)during the said time frames.
Visual impairment has distinct impacts on the activities of older adults. Quantifying the functional impact of visual loss would facilitate targeted rehabilitation. The objectives of this study were to: (1) develop an observational assessment of the functional visual performance of older adults using the Performance Quality Rating Scale (PQRS); (2) test the feasibility and inter-rater agreement in a pilot sample of older adults with visual impairment. A convenience sample of older adults with vision loss (N = 20) performed seven pre-selected activities. Performance was videoed (N = 126 videos) and rated by two raters using specific operational definitions. All participants completed the seven activities with the given resources and 90% of videos were successfully rated using the developed PQRS. Inter-rater agreement was substantial (weighted Kappa = 0.71; 95% confidence interval [CI] = [0.64, 0.79]) for all activities. The developed PQRS for functional vision is feasible, with substantial inter-rater agreement, to assess functional vision of older adults in an outpatient setting.